|By PR Newswire||
|March 27, 2014 06:00 AM EDT|
INDIANAPOLIS, March 27, 2014 /PRNewswire/ -- Polymer Technology Systems, Inc. (PTS, Inc.), the U.S.-based manufacturer of point-of-care diagnostic products, announced today that it is changing its name to Chek Diagnostics. The company is already well known for the CardioChek® family of point-of-care diagnostic products and recently acquired the AICNow® family of products from Bayer Diabetes Care. "We're very excited about the new name because it better reflects our company's ever-broadening portfolio of diagnostic products and technical capabilities," says Robert Huffstodt, President and CEO of Chek Diagnostics. "Our proficiency in providing fast, reliable test results utilizing multiple technologies helps healthcare providers detect and moderate risk factors for millions of people around the world."
According to the American Diabetes Association, heart attack or stroke affect people with diabetes more than twice as often as people without diabetes. CardioChek analyzers provide rapid on-site glucose plus lipid results to help identify at-risk individuals. The A1CNow acquisition strengthens the product portfolio by adding testing capabilities that provide healthcare providers and people with diabetes with an indicator of a patient's average blood glucose control over approximately the past 3 months. These instruments provide rapid results and enable healthcare providers to communicate face-to-face with patients, thus providing optimum point-of-care convenience. "Diabetes and heart disease are two major chronic conditions," says Huffstodt. "Our broader portfolio of products can better assist people in identifying potential risks and helping them lead longer, healthier lives."
The product line diversification lays the groundwork for future growth for Chek Diagnostics. "The two product lines have natural synergies," explains Huffstodt. "We feel that many customers will benefit by incorporating both technologies into their processes." Additionally, the company is developing information management solutions that can enable our diagnostic tools to provide even greater value for healthcare providers.
"First and foremost, we are dedicated to improving health," says Huffstodt. "Our new name, Chek Diagnostics, better reflects our ongoing efforts to deliver a wide range of innovative solutions to today's point-of-care marketplace, while helping prevent and manage disease and enabling people to lead healthier lives. The new name also reflects our excitement about the bright opportunities we see for the future."
About Chek Diagnostics – Chek Diagnostics is a global provider of point-of-care diagnostic products to the healthcare industry. Headquartered in Indianapolis, Indiana, Chek Diagnostics designs, manufactures, and markets products for distribution in over 120 countries around the world. The company has sales offices in Europe, Latin America, and the Pacific Rim. Chek Diagnostics' products include the CardioChek and A1CNow point-of-care systems. The company also offers a variety of single and combination tests for lipids (cholesterols), glucose, and ketones as well as the CardioChek Health Risk Assessment (HRA) software package. For more information, visit www.chekdiagnostics.com or contact Laura Wilkerson at +1-317-870-5610.
All trademarks used or mentioned in this release are protected by law.